JP4227894B2 - グルカゴン様ペプチド1アナログ - Google Patents
グルカゴン様ペプチド1アナログ Download PDFInfo
- Publication number
- JP4227894B2 JP4227894B2 JP2003523182A JP2003523182A JP4227894B2 JP 4227894 B2 JP4227894 B2 JP 4227894B2 JP 2003523182 A JP2003523182 A JP 2003523182A JP 2003523182 A JP2003523182 A JP 2003523182A JP 4227894 B2 JP4227894 B2 JP 4227894B2
- Authority
- JP
- Japan
- Prior art keywords
- glp
- glu
- val
- xaa
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
Xaa7-Xaa8-Glu-Gly-Thr-Xaa12-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Xaa19-Xaa20-Glu-Xaa22-Gln-Ala-Xaa25-Lys-Xaa27-Phe-Ile-Xaa30-Trp-Leu-Xaa33-Lys-Gly-Arg-Xaa37
式1(配列番号1)
[式中、
Xaa7は、L-ヒスチジン、D-ヒスチジン、デスアミノ-ヒスチジン、2-アミノ-ヒスチジン、β-ヒドロキシ-ヒスチジン、ホモヒスチジン、α-フルオロメチル-ヒスチジン、またはα-メチル-ヒスチジンであり、
Xaa8は、Ala、Gly、Val、Leu、Ile、Ser、またはThrであり、
Xaa12は、Phe、Trp、またはTyrであり、
Xaa16は、Val、Trp、Ile、Leu、Phe、またはTyrであり、
Xaa18は、Ser、Trp、Tyr、Phe、Lys、Ile、Leu、またはValであり、
Xaa19は、Tyr、Trp、またはPheであり、
Xaa20は、Leu、Phe、Tyr、またはTrpであり、
Xaa22は、Gly、Glu、Asp、またはLysであり、
Xaa25は、Ala、Val、Ile、またはLeuであり、
Xaa27は、Glu、Ile、またはAlaであり、
Xaa30は、AlaまたはGluであり、
Xaa33は、Val、またはIleであり、かつ
Xaa37は、Gly、His、もしくはNH2であるか、または存在しない。
ただし、本GLP-1化合物は、次に挙げる化合物の配列を持たないものとする:GLP-1(7-37)OH、GLP-1(7-36)-NH2、Gly8-GLP-1(7-37)OH、Gly8-GLP-1(7-36)NH2、Val8-GLP-1(7-37)OH、Val8-GLP-1(7-36)NH2、Lue8-GLP-1(7-37)OH、Leu8-GLP-1(7-36)NH2、Ile8-GLP-1(7-37)OH、Ile8-GLP-1(7-36)NH2、Ser8-GLP-1(7-37)OH、Ser8-GLP-1(7-36)NH2、Thr8-GLP-1(7-37)OH、Thr8-GLP-1(7-36)NH2、Val8-Tyr12-GLP-1(7-37)OH、Val8-Tyr12-GLP-1(7-36)NH2、Val8-Tyr16-GLP-1(7-37)OH、Val8-Tyr16-GLP-1(7-36)NH2、Val8-Glu22-GLP-1(7-37)OH、Val8-Glu22-GLP-1(7-36)NH2、Gly8-Glu22-GLP-1(7-37)OH、Gly8-Glu22-GLP-1(7-36)NH2、Val8-Asp22-GLP-1(7-37)OH、Val8-Asp22-GLP-1(7-36)NH2、Gly8-Asp22-GLP-1(7-37)OH、Gly8-Asp22-GLP-1(7-36)NH2、Val8-Lys22-GLP-1(7-37)OH、Val8-Lys22-GLP-1(7-36)NH2、Gly8-Lys22-GLP-1(7-37)OH、Gly8-Lys22-GLP-1(7-36)NH2、Leu8-Glu22-GLP-1(7-37)OH、Leu8-Glu22-GLP-1(7-36)NH2、Ile8-Glu22-GLP-1(7-37)OH、Ile8-Glu22-GLP-1(7-36)NH2、Leu8-Asp22-GLP-1(7-37)OH、Leu8-Asp22-GLP-1(7-36)NH2、Ile8-Asp22-GLP-1(7-37)OH、Ile8-Asp22-GLP-1(7-36)NH2、Leu8-Lys22-GLP-1(7-37)OH、Leu8-Lys22-GLP-1(7-36)NH2、Ile8-Lys22-GLP-1(7-37)OH、Ile8-Lys22-GLP-1(7-36)NH2、Ser8-Glu22-GLP-1(7-37)OH、Ser8-Glu22-GLP-1(7-36)NH2、Thr8-Glu22-GLP-1(7-37)OH、Thr8-Glu22-GLP-1(7-36)NH2、Ser8-Asp22-GLP-1(7-37)OH、Ser8-Asp22-GLP-1(7-36)NH2、Thr8-Asp22-GLP-1(7-37)OH、Thr8-Asp22-GLP-1(7-36)NH2、Ser8-Lys22-GLP-1(7-37)OH、Ser8-Lys22-GLP-1(7-36)NH2、Thr8-Lys22-GLP-1(7-37)OH、Thr8-Lys22-GLP-1(7-36)NH2、Glu22-GLP-1(7-37)OH、Glu22-GLP-1(7-36)NH2、Asp22-GLP-1(7-37)OH、Asp22-GLP-1(7-36)NH2、Lys22-GLP-1(7-37)OH、Lys22-GLP-1(7-36)NH2、Val8-Ala27-GLP-1(7-37)OH、Val8-Glu22-Ala27-GLP-1(7-37)OH、Val8-Glu30-GLP-1(7-37)OH、Val8-Glu30-GLP-1(7-36)NH2、Gly8-Glu30-GLP-1(7-37)OH、Gly8-Glu30-GLP-1(7-36)NH2、Leu8-Glu30-GLP-1(7-37)OH、Leu8-Glu30-GLP-1(7-36)NH2、Ile8-Glu30-GLP-1(7-37)OH、Ile8-Glu30-GLP-1(7-36)NH2、Ser8-Glu30-GLP-1(7-37)OH、Ser8-Glu30-GLP-1(7-36)NH2、Thr8-Glu30-GLP-1(7-37)OH、Thr8-Glu30-GLP-1(7-36)NH2、Val8-His37-GLP-1(7-37)OH、Val8-His37-GLP-1(7-36)NH2、Gly8-His37-GLP-1(7-37)OH、Gly8-His37-GLP-1(7-36)NH2、Leu8-His37-GLP-1(7-37)OH、Leu8-His37-GLP-1(7-36)NH2、Ile8-His37-GLP-1(7-37)OH、Ile8-His37-GLP-1(7-36)NH2、Ser8-His37-GLP-1(7-37)OH、Ser8-His37-GLP-1(7-36)NH2、Thr8-His37-GLP-1(7-37)OH、Thr8-His37-GLP-1(7-36)NH2]。
Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Tyr-Leu-Glu-Xaa22-Gln-Ala-Xaa25-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Xaa33-Lys-Gly-Arg-Xaa37
式II(配列番号2)
[式中、
Xaa7は、L-ヒスチジン、D-ヒスチジン、デスアミノ-ヒスチジン、2-アミノ-ヒスチジン、β-ヒドロキシ-ヒスチジン、ホモヒスチジン、α-フルオロメチル-ヒスチジン、またはα-メチル-ヒスチジンであり、
Xaa8は、Gly、Ala、Val、Leu、Ile、Ser、またはThrであり、
Xaa16は、Val、Phe、Tyr、またはTrpであり、
Xaa18は、Ser、Tyr、Trp、Phe、Lys、Ile、Leu、またはValであり、
Xaa22は、Gly、Glu、Asp、またはLysであり、
Xaa25は、Ala、Val、Ile、またはLeuであり、
Xaa33は、ValまたはIleであり、かつ
Xaa37は、Gly、もしくはNH2であるか、または存在しない。
ただし、本GLP-1化合物は、次に挙げる化合物の配列を持たないものとする:GLP-1(7-37)OH、GLP-1(7-36)-NH2、Gly8-GLP-1(7-37)OH、Gly8-GLP-1(7-36)NH2、Val8-GLP-1(7-37)OH、Val8-GLP-1(7-36)NH2、Lue8-GLP-1(7-37)OH、Leu8-GLP-1(7-36)NH2、Ile8-GLP-1(7-37)OH、Ile8-GLP-1(7-36)NH2、Ser8-GLP-1(7-37)OH、Ser8-GLP-1(7-36)NH2、Thr8-GLP-1(7-37)OH、Thr8-GLP-1(7-36)NH2、Val8-Tyr16-GLP-1(7-37)OH、Val8-Tyr16-GLP-1(7-36)NH2、Val8-Glu22-GLP-1(7-37)OH、Val8-Glu22-GLP-1(7-36)NH2、Gly8-Glu22-GLP-1(7-37)OH、Gly8-Glu22-GLP-1(7-36)NH2、Val8-Asp22-GLP-1(7-37)OH、Val8-Asp22-GLP-1(7-36)NH2、Gly8-Asp22-GLP-1(7-37)OH、Gly8-Asp22-GLP-1(7-36)NH2、Val8-Lys22-GLP-1(7-37)OH、Val8-Lys22-GLP-1(7-36)NH2、Gly8-Lys22-GLP-1(7-37)OH、Gly8-Lys22-GLP-1(7-36)NH2、Leu8-Glu22-GLP-1(7-37)OH、Leu8-Glu22-GLP-1(7-36)NH2、Ile8-Glu22-GLP-1(7-37)OH、Ile8-Glu22-GLP-1(7-36)NH2、Leu8-Asp22-GLP-1(7-37)OH、Leu8-Asp22-GLP-1(7-36)NH2、Ile8-Asp22-GLP-1(7-37)OH、Ile8-Asp22-GLP-1(7-36)NH2、Leu8-Lys22-GLP-1(7-37)OH、Leu8-Lys22-GLP-1(7-36)NH2、Ile8-Lys22-GLP-1(7-37)OH、Ile8-Lys22-GLP-1(7-36)NH2、Ser8-Glu22-GLP-1(7-37)OH、Ser8-Glu22-GLP-1(7-36)NH2、Thr8-Glu22-GLP-1(7-37)OH、Thr8-Glu22-GLP-1(7-36)NH2、Ser8-Asp22-GLP-1(7-37)OH、Ser8-Asp22-GLP-1(7-36)NH2、Thr8-Asp22-GLP-1(7-37)OH、Thr8-Asp22-GLP-1(7-36)NH2、Ser8-Lys22-GLP-1(7-37)OH、Ser8-Lys22-GLP-1(7-36)NH2、Thr8-Lys22-GLP-1(7-37)OH、Thr8-Lys22-GLP-1(7-36)NH2、Glu22-GLP-1(7-37)OH、Glu22-GLP-1(7-36)NH2、Asp22-GLP-1(7-37)OH、Asp22-GLP-1(7-36)NH2、Lys22-GLP-1(7-37)OH、Lys22-GLP-1(7-36)NH2]。
7His-Ala-Glu-10Gly-Thr-Phe-Thr-Ser-15Asp-Val-Ser-Ser-Tyr-20Leu-Glu-Gly-Gln-Ala-25Ala-Lys-Glu-Phe-Ile-30Ala-Trp-Leu-Val-Lys-35Gly-Arg-37Gly
(配列番号3)。
当技術分野での慣例により、GLP-1(7-37)OHのアミノ末端には残基番号7が割り当てられ、カルボキシ末端には番号37が割り当てられている。配列番号3に示すように、ポリペプチド中の他のアミノ酸には連続した番号が与えられる。例えば12位はフェニルアラニンであり、22位はグリシンである。明記しない場合、C末端は通常のカルボキシル型をとる。
Xaa7-Xaa8-Glu-Gly-Thr-Xaa12-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Xaa19-Xaa20-Glu-Xaa22-Gln-Ala-Xaa25-Lys-Xaa27-Phe-Ile-Xaa30-Trp-Leu-Xaa33-Lys-Gly-Arg-Xaa37
式1(配列番号1)
[式中、
Xaa7は、L-ヒスチジン、D-ヒスチジン、デスアミノ-ヒスチジン、2-アミノ-ヒスチジン、β-ヒドロキシ-ヒスチジン、ホモヒスチジン、α-フルオロメチル-ヒスチジン、またはα-メチル-ヒスチジンであり、
Xaa8は、Ala、Gly、Val、Leu、Ile、Ser、またはThrであり、
Xaa12は、Phe、Trp、またはTyrであり、
Xaa16は、Val、Trp、Ile、Leu、Phe、またはTyrであり、
Xaa18は、Ser、Trp、Tyr、Phe、Lys、Ile、Leu、またはValであり、
Xaa19は、Tyr、Trp、またはPheであり、
Xaa20は、Leu、Phe、Tyr、またはTrpであり、
Xaa22は、Gly、Glu、Asp、Lysであり、
Xaa25は、Ala、Val、Ile、またはLeuであり、
Xaa27は、Glu、Ile、またはAlaであり、
Xaa30は、AlaまたはGluであり、
Xaa33は、Val、またはIleであり、かつ
Xaa37は、Gly、His、もしくはNH2であるか、または存在しない。
ただし、本GLP-1化合物は、次に挙げる化合物の配列を持たないものとする:GLP-1(7-37)OH、GLP-1(7-36)-NH2、Gly8-GLP-1(7-37)OH、Gly8-GLP-1(7-36)NH2、Val8-GLP-1(7-37)OH、Val8-GLP-1(7-36)NH2、Lue8-GLP-1(7-37)OH、Leu8-GLP-1(7-36)NH2、Ile8-GLP-1(7-37)OH、Ile8-GLP-1(7-36)NH2、Ser8-GLP-1(7-37)OH、Ser8-GLP-1(7-36)NH2、Thr8-GLP-1(7-37)OH、Thr8-GLP-1(7-36)NH2、Val8-Tyr12-GLP-1(7-37)OH、Val8-Tyr12-GLP-1(7-36)NH2、Val8-Tyr16-GLP-1(7-37)OH、Val8-Tyr16-GLP-1(7-36)NH2、Val8-Glu22-GLP-1(7-37)OH、Val8-Glu22-GLP-1(7-36)NH2、Gly8-Glu22-GLP-1(7-37)OH、Gly8-Glu22-GLP-1(7-36)NH2、Val8-Asp22-GLP-1(7-37)OH、Val8-Asp22-GLP-1(7-36)NH2、Gly8-Asp22-GLP-1(7-37)OH、Gly8-Asp22-GLP-1(7-36)NH2、Val8-Lys22-GLP-1(7-37)OH、Val8-Lys22-GLP-1(7-36)NH2、Gly8-Lys22-GLP-1(7-37)OH、Gly8-Lys22-GLP-1(7-36)NH2、Leu8-Glu22-GLP-1(7-37)OH、Leu8-Glu22-GLP-1(7-36)NH2、Ile8-Glu22-GLP-1(7-37)OH、Ile8-Glu22-GLP-1(7-36)NH2、Leu8-Asp22-GLP-1(7-37)OH、Leu8-Asp22-GLP-1(7-36)NH2、Ile8-Asp22-GLP-1(7-37)OH、Ile8-Asp22-GLP-1(7-36)NH2、Leu8-Lys22-GLP-1(7-37)OH、Leu8-Lys22-GLP-1(7-36)NH2、Ile8-Lys22-GLP-1(7-37)OH、Ile8-Lys22-GLP-1(7-36)NH2、Ser8-Glu22-GLP-1(7-37)OH、Ser8-Glu22-GLP-1(7-36)NH2、Thr8-Glu22-GLP-1(7-37)OH、Thr8-Glu22-GLP-1(7-36)NH2、Ser8-Asp22-GLP-1(7-37)OH、Ser8-Asp22-GLP-1(7-36)NH2、Thr8-Asp22-GLP-1(7-37)OH、Thr8-Asp22-GLP-1(7-36)NH2、Ser8-Lys22-GLP-1(7-37)OH、Ser8-Lys22-GLP-1(7-36)NH2、Thr8-Lys22-GLP-1(7-37)OH、Thr8-Lys22-GLP-1(7-36)NH2、Glu22-GLP-1(7-37)OH、Glu22-GLP-1(7-36)NH2、Asp22-GLP-1(7-37)OH、Asp22-GLP-1(7-36)NH2、Lys22-GLP-1(7-37)OH、Lys22-GLP-1(7-36)NH2、Val8-Ala27-GLP-1(7-37)OH、Val8-Glu22-Ala27-GLP-1(7-37)OH、Val8-Glu30-GLP-1(7-37)OH、Val8-Glu30-GLP-1(7-36)NH2、Gly8-Glu30-GLP-1(7-37)OH、Gly8-Glu30-GLP-1(7-36)NH2、Leu8-Glu30-GLP-1(7-37)OH、Leu8-Glu30-GLP-1(7-36)NH2、Ile8-Glu30-GLP-1(7-37)OH、Ile8-Glu30-GLP-1(7-36)NH2、Ser8-Glu30-GLP-1(7-37)OH、Ser8-Glu30-GLP-1(7-36)NH2、Thr8-Glu30-GLP-1(7-37)OH、Thr8-Glu30-GLP-1(7-36)NH2、Val8-His37-GLP-1(7-37)OH、Val8-His37-GLP-1(7-36)NH2、Gly8-His37-GLP-1(7-37)OH、Gly8-His37-GLP-1(7-36)NH2、Leu8-His37-GLP-1(7-37)OH、Leu8-His37-GLP-1(7-36)NH2、Ile8-His37-GLP-1(7-37)OH、Ile8-His37-GLP-1(7-36)NH2、Ser8-His37-GLP-1(7-37)OH、Ser8-His37-GLP-1(7-36)NH2、Thr8-His37-GLP-1(7-37)OH、Thr8-His37-GLP-1(7-36)NH2]。
Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Tyr-Leu-Glu-Xaa22-Gln-Ala-Xaa25-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Xaa33-Lys-Gly-Arg-Xaa37
式II(配列番号2)
[式中、
Xaa7は、L-ヒスチジン、D-ヒスチジン、デスアミノ-ヒスチジン、2-アミノ-ヒスチジン、β-ヒドロキシ-ヒスチジン、ホモヒスチジン、α-フルオロメチル-ヒスチジン、またはα-メチル-ヒスチジンであり、
Xaa8は、Gly、Ala、Val、Leu、Ile、Ser、またはThrであり、
Xaa16は、Val、Phe、Tyr、またはTrpであり、
Xaa18は、Ser、Tyr、Trp、Phe、Lys、Ile、Leu、またはValであり、
Xaa22は、Gly、Glu、Asp、またはLysであり、
Xaa25は、Ala、Val、Ile、またはLeuであり、
Xaa33は、ValまたはIleであり、かつ
Xaa37は、Gly、もしくはNH2であるか、または存在しない。
ただし、本GLP-1化合物は、次に挙げる化合物の配列を持たないものとする:GLP-1(7-37)OH、GLP-1(7-36)-NH2、Gly8-GLP-1(7-37)OH、Gly8-GLP-1(7-36)NH2、Val8-GLP-1(7-37)OH、Val8-GLP-1(7-36)NH2、Lue8-GLP-1(7-37)OH、Leu8-GLP-1(7-36)NH2、Ile8-GLP-1(7-37)OH、Ile8-GLP-1(7-36)NH2、Ser8-GLP-1(7-37)OH、Ser8-GLP-1(7-36)NH2、Thr8-GLP-1(7-37)OH、Thr8-GLP-1(7-36)NH2、Val8-Tyr16-GLP-1(7-37)OH、Val8-Tyr16-GLP-1(7-36)NH2、Val8-Glu22-GLP-1(7-37)OH、Val8-Glu22-GLP-1(7-36)NH2、Gly8-Glu22-GLP-1(7-37)OH、Gly8-Glu22-GLP-1(7-36)NH2、Val8-Asp22-GLP-1(7-37)OH、Val8-Asp22-GLP-1(7-36)NH2、Gly8-Asp22-GLP-1(7-37)OH、Gly8-Asp22-GLP-1(7-36)NH2、Val8-Lys22-GLP-1(7-37)OH、Val8-Lys22-GLP-1(7-36)NH2、Gly8-Lys22-GLP-1(7-37)OH、Gly8-Lys22-GLP-1(7-36)NH2、Leu8-Glu22-GLP-1(7-37)OH、Leu8-Glu22-GLP-1(7-36)NH2、Ile8-Glu22-GLP-1(7-37)OH、Ile8-Glu22-GLP-1(7-36)NH2、Leu8-Asp22-GLP-1(7-37)OH、Leu8-Asp22-GLP-1(7-36)NH2、Ile8-Asp22-GLP-1(7-37)OH、Ile8-Asp22-GLP-1(7-36)NH2、Leu8-Lys22-GLP-1(7-37)OH、Leu8-Lys22-GLP-1(7-36)NH2、Ile8-Lys22-GLP-1(7-37)OH、Ile8-Lys22-GLP-1(7-36)NH2、Ser8-Glu22-GLP-1(7-37)OH、Ser8-Glu22-GLP-1(7-36)NH2、Thr8-Glu22-GLP-1(7-37)OH、Thr8-Glu22-GLP-1(7-36)NH2、Ser8-Asp22-GLP-1(7-37)OH、Ser8-Asp22-GLP-1(7-36)NH2、Thr8-Asp22-GLP-1(7-37)OH、Thr8-Asp22-GLP-1(7-36)NH2、Ser8-Lys22-GLP-1(7-37)OH、Ser8-Lys22-GLP-1(7-36)NH2、Thr8-Lys22-GLP-1(7-37)OH、Thr8-Lys22-GLP-1(7-36)NH2、Glu22-GLP-1(7-37)OH、Glu22-GLP-1(7-36)NH2、Asp22-GLP-1(7-37)OH、Asp22-GLP-1(7-36)NH2、Lys22-GLP-1(7-37)OH、Lys22-GLP-1(7-36)NH2]。
固相t-Boc法による本発明のGLP-1化合物の製造
約0.5〜0.6グラム(0.38〜0.45mmol)のBoc Gly-PAM樹脂を、標準の60ml反応容器に入れ、Applied Biosystems ABI430Aペプチド合成装置で、ダブルカップリングを行った。以下の側鎖保護アミノ酸(Bocアミノ酸の2mmolカートリッジ)をMidwest Biotech(インディアナ州フィッシャーズ)から入手して、合成に使用した:
Arg-Tosyl(TOS)、Asp-δ-シクロヘキシルエステル(CHXL)、Glu-δ-シクロヘキシルエステル(CHXL)、His-ベンジルオキシメチル(BOM)、Lys-2-クロロベンジルオキシカルボニル(2Cl-Z)、Met-スルホキシド(O)、Ser-O-ベンジルエーテル(OBzl)、Thr-O-ベンジルエーテル(OBzl)、Trp-ホルミル(CHO)およびTyr-2-ブロモベンジルオキシカルボニル(2Br-Z)ならびにBoc Gly PAM樹脂。トリフルオロ酢酸(TFA)、ジイソプロピルエチルアミン(DIEA)、DMF中の0.5Mヒドロキシベンゾトリアゾール(HOBt)、ジクロロメタン中の0.5Mジシクロヘキシルカルボジイミド(DCC)は、PE-Applied Biosystems(カリフォルニア州フォスターシティ)から購入した。ジメチルホルムアミド(DMF, Burdick and Jackson)およびジクロロメタン(DCM, Mallinkrodt)は、Mays Chemical Co.(インディアナ州インディアナポリス)から購入した。
固相F-Moc法による本発明のGLP-1化合物の製造
約114mg(50mmol)のFMOC Gly WANG樹脂(NovaBiochem(カリフォルニア州ラホーヤ)から購入)を、96ウェル反応ブロックの所定の各ウェルに入れ、Advanced ChemTech 396ペプチド合成装置でダブルカップリングを行った。C末端アミドを持つアナログは75mg(50μmol)のRink Amide AM樹脂(NovaBiochem, カリフォルニア州ラホーヤ)を使って製造した。
GLP凝集アッセイ:
本発明のGLPペプチドを、それらが溶液中で凝集する能力について解析した。概説すると、適切な緩衝液中で、溶解した状態のペプチドを、高い温度で撹拌しつつ、350nmでの濁度を時間の関数として記録した。凝集が始まるまでの時間を測定することにより、これらの負荷条件下での、与えられたGLP分子の凝集能力を定量化した。
既に凝集している物質をすべて溶解させるために、GLP-1化合物を、まずアルカリ性条件(pH10.5)で30分間溶解した。次にその溶液をpH7.4に調節し、濾過した。具体的には、4mgの凍結乾燥GLP-1化合物を3mlの10mMリン酸塩/10mMクエン酸塩に溶解した。pHを10.0〜10.5に調節し、それを30分間保った。その溶液をHClでpH7.4に調節し、適当なフィルター、例えばMillex GVシリンジフィルター(Millipore Corporation, マサチューセッツ州ベッドフォード)などを通して濾過した。次に、この溶液を、0.3mg/mLのタンパク質を含む最終試料が得られるように、10mMクエン酸塩、10mMリン酸塩、150mM NaClに希釈し、pH7.4〜7.5に調節した。試料を石英キュベットに入れて37℃でインキュベートした。AVIV Model 14DS UV-VIS分光光度計(ニュージャージー州レークウッド)を使って、5分毎に溶液の濁度を350nmで測定した。測定前の30秒間と測定中は、Starna Cells, Inc.(カリフォルニア州アタスカデロ)製の磁気撹拌子を使って、溶液を撹拌した。350nmでのODの増加は、GLP-ペプチドの凝集を表す。Drakeらの方法(Arvinte T, Cudd AおよびDrake AF(1993)J. Bio. Chem. 268, 6415-6422)に従い、前増加期と増加期の線型フィットの交点によって、凝集までの時間を概算した。
本発明のGLP-1化合物によるGLP-1受容体の活性化
GelfandらのEP 619,322や米国特許第5,120,712号にそれぞれ記載されているようなインビトロアッセイを使って、本発明GLP-1化合物のGLP-1受容体活性化能を評価した。これらの文献の教示する内容は参照によりすべて本明細書に組み込まれるものとする。Val8-GLP-1(7-37)OHの活性を対するこれらの化合物の相対活性を表1に示す。
ラットにおける経静脈的グルコース負荷試験(IVGTT)
溶液の注入と採血が容易にできるように、絶食したウィスター雄ラットにダブルカニュレーション術を施した。頸静脈カニューレを通して、ラットに10%グルコース溶液をボーラス注入した後、所定の量のGLP-1化合物を含む溶液を注入した。ラットには、0.01、0.03、0.1、0.3、1、および10μg/kgのGLP-1化合物を注入した。GLP-1化合物注入の2、4、6、10、および30分後に、頸動脈カニューレを通して血液を採取し、分析した。各試料の血漿インスリンレベルおよび血漿グルコースレベルを測定した。平均インスリンレベルよび平均グルコースレベルを図1、2および3に図示する。
Claims (1)
- His-Val 8 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu 22 -Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Ile 33 -Lys-Gly-Arg-Gly-OH のアミノ酸配列を含む GLP-1 化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31457301P | 2001-08-23 | 2001-08-23 | |
PCT/US2002/021325 WO2003018516A2 (en) | 2001-08-23 | 2002-08-14 | Glucagon-like peptide-1 analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005528321A JP2005528321A (ja) | 2005-09-22 |
JP4227894B2 true JP4227894B2 (ja) | 2009-02-18 |
Family
ID=23220481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003523182A Expired - Fee Related JP4227894B2 (ja) | 2001-08-23 | 2002-08-14 | グルカゴン様ペプチド1アナログ |
Country Status (11)
Country | Link |
---|---|
US (1) | US7101843B2 (ja) |
EP (1) | EP1432730A4 (ja) |
JP (1) | JP4227894B2 (ja) |
KR (1) | KR100593348B1 (ja) |
AU (1) | AU2002322403A1 (ja) |
BR (1) | BR0212080A (ja) |
CA (1) | CA2458371A1 (ja) |
HU (1) | HUP0501192A3 (ja) |
IL (1) | IL160493A0 (ja) |
MX (1) | MXPA04001525A (ja) |
WO (1) | WO2003018516A2 (ja) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280004B1 (en) | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
WO2003072143A1 (en) * | 2002-02-27 | 2003-09-04 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
KR100733940B1 (ko) | 2003-03-19 | 2007-06-29 | 일라이 릴리 앤드 캄파니 | 폴리에틸렌 글리콜이 연결된 glp-1 화합물 |
ES2383752T3 (es) | 2003-05-15 | 2012-06-26 | Trustees Of Tufts College | Analogos estables de GLP-1 |
CN102940879B (zh) | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
CN1812808B (zh) | 2003-06-03 | 2012-07-04 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
BRPI0506694A (pt) | 2004-01-08 | 2007-05-02 | Theratechnologies Inc | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
WO2005112977A2 (en) * | 2004-04-23 | 2005-12-01 | Pharmain, Ltd. | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
EP1776720A4 (en) * | 2004-06-09 | 2008-07-09 | Redwood Renewables Llc | ENTVULKANIZED PHOTOVOLTAIC ROOF TILES |
JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
MX2007002189A (es) | 2004-08-23 | 2008-01-11 | Mannkind Corp | Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos. |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
DK1888103T3 (da) * | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
JPWO2007049695A1 (ja) * | 2005-10-26 | 2009-04-30 | 中外製薬株式会社 | 凝集性glp−1アナログおよび徐放性医薬組成物 |
HUE029798T2 (en) * | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
WO2007076371A2 (en) * | 2005-12-19 | 2007-07-05 | Pharmain Corporation | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US8178495B2 (en) * | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
CA2634034A1 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
IN2015DN00888A (ja) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
DE602007009377D1 (de) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
CN102274557B (zh) | 2006-08-09 | 2014-12-03 | 精达制药公司 | 渗透性递送系统和活塞组件 |
JO2945B1 (en) * | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
DK2157967T3 (da) | 2007-04-23 | 2013-04-08 | Intarcia Therapeutics Inc | Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
EP3260129A1 (en) * | 2007-08-03 | 2017-12-27 | Eli Lilly and Company | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
RU2467741C2 (ru) * | 2007-10-24 | 2012-11-27 | Маннкайнд Корпорейшн | Доставка активных веществ |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
CA2703338A1 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Method of preventing adverse effects by glp-1 |
US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
AU2009246894A1 (en) * | 2008-05-14 | 2009-11-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of somatostatin-dopamine conjugates |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101933816B1 (ko) | 2008-06-13 | 2019-03-29 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
WO2009155581A1 (en) | 2008-06-20 | 2009-12-23 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
US8889618B2 (en) | 2008-11-07 | 2014-11-18 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (GLP-1) |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PL2405963T3 (pl) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Urządzenie, układ i sposób pomiaru oporu inhalatora |
BRPI1013154B1 (pt) | 2009-06-12 | 2020-04-07 | Mannkind Corp | Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação |
HUE032703T2 (en) * | 2009-08-14 | 2017-10-30 | Phasebio Pharmaceuticals Inc | Modified vasoactive intestinal peptides |
LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
EP2565202A4 (en) | 2010-04-30 | 2013-10-30 | Sanwa Kagaku Kenkyusho Co | PEPTIDE FOR IMPROVING THE IN VIVO STABILITY OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE OR ANALOGUES AND PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ANALOGUES HAVING IN VIVO STABILITY IMPROVEMENT |
EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
MX359281B (es) | 2010-06-21 | 2018-09-21 | Mannkind Corp | Sistema y metodos para suministrar un farmaco en polvo seco. |
EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS |
WO2012000118A1 (en) | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
WO2012061466A2 (en) | 2010-11-02 | 2012-05-10 | The General Hospital Corporation | Methods for treating steatotic disease |
CN103298456A (zh) * | 2011-01-19 | 2013-09-11 | 诺沃—诺迪斯克有限公司 | Glp-1颗粒和组合物 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013006692A2 (en) | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
IN2014DN03093A (ja) | 2011-10-24 | 2015-05-15 | Mannkind Corp | |
WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
US9777039B2 (en) | 2012-11-01 | 2017-10-03 | Ipsen Pharma S.A.S. | Somatostatin analogs and dimers thereof |
TWI523863B (zh) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素-多巴胺嵌合體類似物 |
KR102499439B1 (ko) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
CA2918369C (en) | 2013-07-18 | 2021-06-29 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
WO2015172046A1 (en) | 2014-05-08 | 2015-11-12 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
EP3463413A4 (en) * | 2016-05-25 | 2020-03-04 | Merck Sharp & Dohme Corp. | PARTIAL INSULIN RECEPTOR AGONISTS |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
CN113195524A (zh) | 2018-10-11 | 2021-07-30 | 因塔西亚治疗公司 | 人类胰淀素类似物多肽和使用方法 |
EP4281039A2 (en) | 2021-01-25 | 2023-11-29 | Mylan Ireland Limited | Pharmaceutical glp peptide compositions and methods of preparation thereof |
CA3223530A1 (en) * | 2021-06-14 | 2022-12-22 | Darbix Llc | Glp-1 receptor agonists having improved pharmacological and drug delivery properties |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
EP1061946B1 (en) | 1998-02-27 | 2004-04-28 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
EP1062240B1 (en) * | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
EP1306091A3 (en) * | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
ES2315226T3 (es) * | 1999-03-17 | 2009-04-01 | Novo Nordisk A/S | Metodo de acilacion de peptidos y proteinas. |
HU229208B1 (en) * | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
BR0116024A (pt) * | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
-
2002
- 2002-08-14 HU HU0501192A patent/HUP0501192A3/hu unknown
- 2002-08-14 CA CA002458371A patent/CA2458371A1/en not_active Abandoned
- 2002-08-14 US US10/485,619 patent/US7101843B2/en not_active Expired - Fee Related
- 2002-08-14 IL IL16049302A patent/IL160493A0/xx unknown
- 2002-08-14 MX MXPA04001525A patent/MXPA04001525A/es not_active Application Discontinuation
- 2002-08-14 AU AU2002322403A patent/AU2002322403A1/en not_active Abandoned
- 2002-08-14 EP EP02756392A patent/EP1432730A4/en not_active Withdrawn
- 2002-08-14 JP JP2003523182A patent/JP4227894B2/ja not_active Expired - Fee Related
- 2002-08-14 BR BRPI0212080-1A patent/BR0212080A/pt not_active IP Right Cessation
- 2002-08-14 WO PCT/US2002/021325 patent/WO2003018516A2/en active Application Filing
- 2002-08-14 KR KR1020047002632A patent/KR100593348B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002322403A1 (en) | 2003-03-10 |
JP2005528321A (ja) | 2005-09-22 |
CA2458371A1 (en) | 2003-03-06 |
WO2003018516A3 (en) | 2004-02-26 |
BR0212080A (pt) | 2006-04-04 |
US20040198654A1 (en) | 2004-10-07 |
EP1432730A2 (en) | 2004-06-30 |
KR100593348B1 (ko) | 2006-06-26 |
MXPA04001525A (es) | 2004-05-31 |
US7101843B2 (en) | 2006-09-05 |
IL160493A0 (en) | 2004-07-25 |
HUP0501192A2 (en) | 2006-03-28 |
KR20040039302A (ko) | 2004-05-10 |
WO2003018516A2 (en) | 2003-03-06 |
EP1432730A4 (en) | 2006-10-11 |
HUP0501192A3 (en) | 2006-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4227894B2 (ja) | グルカゴン様ペプチド1アナログ | |
JP4716641B2 (ja) | グルカゴン様ペプチド−1類似体 | |
JP4282485B2 (ja) | 伸長グルカゴン様ペプチド−1アナログ | |
US8097586B2 (en) | Modified exedins and uses thereof | |
AU2001264791A1 (en) | Glucagon-like peptide-1 analogs | |
JP2006520818A (ja) | ポリエチレングリコール結合glp−1化合物 | |
JP2006520818A5 (ja) | ||
AU2003200839A2 (en) | Extended glucagon-like peptide-1 analogs | |
US20060252693A1 (en) | Glucagon-like peptide-1 analogs | |
ZA200210098B (en) | Glucagon-like peptide-1 analogs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080827 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080903 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080911 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080925 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081118 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081201 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111205 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |